Biotech
Thursday, January 18th, 2024 6:48 pm EDT
Key Points
- Drugmakers are racing to enter the growing market for weight loss drugs, which is expected to be worth tens of billions in the next decade.
- Lesser-known contenders, including Boehringer Ingelheim, Terns Pharmaceuticals, Viking Therapeutics, Structure Therapeutics, and Altimmune, are aiming to compete with dominant players Novo Nordisk and Eli Lilly.
- Boehringer Ingelheim, in collaboration with Zealand Pharma, is developing an experimental drug called survodutide targeting gut hormones GLP-1 and glucagon. The drug is in late-stage study, and mid-stage trial results showed up to 19% weight loss in overweight or obese patients.
- Terns Pharmaceuticals is conducting an early-stage trial for its oral weight loss drug targeting GLP-1, with initial 28-day data expected in the second half of 2024.
- Viking Therapeutics is developing weight loss drugs targeting GLP-1 and GIP, with mid-stage trial data expected in the first half of the year.
- Structure Therapeutics is developing an obesity pill, and Altimmune has seen a stock surge after mid-stage trial data for its obesity injection, pemvidutide, showed 15.6% weight loss.
- Large drugmakers, such as Sanofi and Bayer, are considering entering the weight loss drug market in the future, signaling potential further competition and innovation in the sector.
In the increasingly competitive market for weight loss drugs, drugmakers are vying to capture a share of what is anticipated to be a lucrative sector potentially worth tens of billions of dollars within the next decade. The demand for effective weight loss treatments is on the rise, and lesser-known contenders are entering the race to challenge dominant players like Novo Nordisk and Eli Lilly. Some of the companies positioning themselves in this market include Boehringer Ingelheim, which, in collaboration with Zealand Pharma, is developing an experimental drug called survodutide targeting gut hormones GLP-1 and glucagon. Terns Pharmaceuticals is in the early stages of developing an oral weight loss drug targeting GLP-1. Viking Therapeutics is working on drugs that target GLP-1 and GIP, with mid-stage trial data expected in the first half of the year. Structure Therapeutics is developing an obesity pill, and Altimmune has seen a stock surge after mid-stage trial data for its obesity injection, pemvidutide, showed 15.6% weight loss. Larger players, including Sanofi and Bayer, are also contemplating entry into the weight loss drug market, signaling the potential for further competition and innovation in this space. With Goldman Sachs analysts projecting 15 million U.S. adults on obesity medications by 2030, companies are seizing the opportunity presented by the growing demand for effective weight loss solutions. As the race intensifies, the landscape of weight loss drugs is set to evolve with new entrants and established players seeking to address this significant public health concern.
For the full original article on CNBC, please click here: https://www.cnbc.com/2024/01/17/weight-loss-drugs-boehringer-ingelheim-terns-viking-may-join-market.html
